Educate Why Aduhelm Isn’t a Miracle for Alzheimer’s

You’ll hear controversy about Aduhelm (aducanumab), the first new med for Alzheimer’s disease in almost 20 years.

It’s a monoclonal antibody given as an IV infusion every 4 weeks.

Patients with Alzheimer’s and their families are often looking for a glimmer of hope.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote